Bioatla investor relations
WebBioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody ... 484 … WebMar 14, 2024 · See the latest BioAtla Inc Ordinary Shares stock price (NASDAQ:BCAB), related news, valuation, dividends and more to help you make your investing decisions. ... Investor Relations BioAtla Inc ...
Bioatla investor relations
Did you know?
WebBioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics ™ (CAB) platform exploits the unique microenvironment …
WebApr 3, 2024 · Investor FAQs; Email Alerts; Contact IR; SEC Filings Group. Filing year. Items per page. Filing date Form Description Filing Group View; 04/03/23: 4: Statement of changes in beneficial ownership of securities. 3,4,5. 0001209191-23-022427.pdf. 0001209191-23-022427.rtf ... BioAtla ® is a leading San ... WebBioAtla, Inc. 11085 Torreyana Road . San Diego, California, 92121 ... presentations, webcasts and our investor relations website. While not all of the information that we …
WebDec 15, 2024 · BioAtla is registered under the ticker NASDAQ:BCAB . Their stock opened with $18.00 in its Dec 15, 2024 IPO. BioAtla is funded by 20 investors. Vivo Capital and Acuta Capital Partners are the most recent investors. BioAtla has a post-money valuation in the range of $500M to $1B as of Jul 16, 2024, according to PrivCo. WebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We …
WebNov 17, 2024 · Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 12% of BioAtla shares.
WebMar 23, 2024 · View Bioatla (www.bioatla.com) location in California, United States , revenue, industry and description. ... NASDAQ:BCAB) Q4 2024 Earnings Call Transcript March 23, 2024 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, LifeSci Advisors, LLCJay Short -... Mar 24, 2024. seekingalpha.com . bittersweet foodsWebAug 17, 2024 · BioAtla is not a large company by global standards. It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors. datatypeconverter jar fileWebBioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based … data type computingWebNov 13, 2024 · BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public … datatypeconverter noclassdeffounderrorWebMar 23, 2024 · Access Bioatla Inc (BCAB) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr bitter sweet foodWebMay 12, 2024 · BioAtla, Inc. May 12, 2024, 18:26 ET. SAN DIEGO, May 12, 2024 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB ), a global clinical-stage biotechnology company focused on the development of ... data type conversion block in simulinkWebBioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics ™ (CAB) platform … data type conversion in sql server